Your browser doesn't support javascript.
loading
CRISPR/Cas9 genome editing approaches for psychiatric research
Gutiérrez-Rodríguez, Araceli; Cruz-Fuentes, Carlos S.; Genis-Mendoza, Alma D.; Nicolini, Humberto.
  • Gutiérrez-Rodríguez, Araceli; Instituto Nacional de Medicina Genómica. Laboratorio Genómica de Enfermedades Psiquiátricas y Neurodegenerativas. Ciudad de México. MX
  • Cruz-Fuentes, Carlos S.; Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz. Subdirección de Investigaciones Clínicas. Departamento de Genética Psiquiatríca. Ciudad de México. MX
  • Genis-Mendoza, Alma D.; Instituto Nacional de Medicina Genómica. Laboratorio Genómica de Enfermedades Psiquiátricas y Neurodegenerativas. Ciudad de México. MX
  • Nicolini, Humberto; Instituto Nacional de Medicina Genómica. Laboratorio Genómica de Enfermedades Psiquiátricas y Neurodegenerativas. Ciudad de México. MX
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 45(2): 137-145, Mar.-Apr. 2023. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1439554
ABSTRACT
Currently, genome editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR/Cas9), are predominantly used to model genetic diseases. This genome editing system can correct point or frameshift mutations in risk genes. Here, we analyze and discuss the advantages of genome editing, its current applications, and the feasibility of the CRISPR/Cas9 system in research on psychiatric disorders. These disorders produce cognitive and behavioral alterations and their etiology is associated with polygenetic and environmental factors. CRISPR/Cas9 may reveal the biological mechanisms of psychiatric disorders at a basic research level, translating a suitable clinical approach for use in the diagnosis and treatment of psychiatric disorders. Genetic diagnosis and treatment for these disorders have not yet been fully established in psychiatry due to the limited understanding of their heterogeneity and polygenicity. We discuss the challenges and ethical issues in using CRISPR/Cas9 as a tool for diagnosis or gene therapy.


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2023 Type: Article Affiliation country: Mexico Institution/Affiliation country: Instituto Nacional de Medicina Genómica/MX / Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz/MX

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study Language: English Journal: Braz. J. Psychiatry (São Paulo, 1999, Impr.) Journal subject: Psychiatry Year: 2023 Type: Article Affiliation country: Mexico Institution/Affiliation country: Instituto Nacional de Medicina Genómica/MX / Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz/MX